The synthetic biology industry is expected to experience rapid growth in the near future. Companies are increasingly investing in the research and development of synthetic biology, which is leading to a wide range of applications in fields such as medicine, agriculture, and manufacturing. This growth is being driven by a number of factors, including the increasing availability of data and tools, the potential to produce new products, and the potential to reduce costs. In addition, the emergence of new technologies such as CRISPR-Cas9, which allows for precise genetic manipulation, is likely to accelerate the development of synthetic biology. In the coming years, the industry is expected to expand across multiple sectors, from biotechnology to healthcare and manufacturing. This is likely to create a range of opportunities for entrepreneurs, investors, and companies looking to capitalize on the potential of synthetic biology.

Synthetic Biology market in terms of revenue was estimated to be worth $11.4 billion in 2022 and is poised to reach $35.7 billion by 2027, growing at a CAGR of 25.6% from 2022 to 2027 according to a latest report published by MarketsandMarkets™. Declining cost of DNA sequencing, increased investment in RD and rise in number of fundings for synthetic biology are some of the major factors propelling the growth of this market. However, biosafety, biosecurity, and ethical concerns related to synthetic biology is likely to hamper the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889

Based on tools, the synthetic biology market is broadly segmented into oligonucleotides synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids. In 2021, oligonucleotides synthetic DNA segment accounted for the largest share. The dominance of the segment is attributable to factors such as increasing demand for synthetic DNA, synthetic RNA, and synthetic genes, which are used in a wide range of applications across various industries.

Based on application, the synthetic biology market is segmented into medical applications, industrial applications, food agriculture, and environmental applications. In 2021, medical applications segment accounted for the largest share of synthetic biology market. Factors such as the widespread research on novel treatment coupled with the availability of huge private and public funding are some of the major factors driving the segmental growth.

The global synthetic biology market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America dominated the synthetic biology market followed by Europe and Asia Pacific respectively. Asia Pacific region is likely to grow at faster pace during the forecast period of 2022-2027. The factors attributable to the faster growth rate are increasing investment in synthetic biology owing to higher adoption in various applications. The overall share of this region in the global market is gradually increasing, owing to growth in research activities and biologic therapeutics manufacturing. High-growth regions such as China, Japan, Australia, and Singapore are expected to be major contributors to the Asia Pacific synthetic biology market.

Key Market Players:

Key market players operating in synthetic biology market players are Thermo Fisher Scientific (US), Merck KGaA (Germany), Agilent Technologies (US), Novozymes (Denmark), Amyris (US), Precigen (US), GenScript Biotech (China), Twist Bioscience (US), Codexis (US), and Eurofins Scientific (Luxembourg).

Enquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=889

Recent Developments:

• In January 2021, Novozymes launched Frontia GlutenEx. It would help wheat processors increase their gluten protein recovery and, at the same time, cut down on energy consumption.
• In February 2021, Merck partnered with BioNTech (Germany) to supply lipids for the production of Pfizer-BioNTech COVID-19 Vaccine (BNT162b2).
• In January 2021, Merck acquired AmpTec (Germany). With this acquisition, the company strengthened its product portfolio to develop and manufacture mRNA for utilizing vaccines, treatments, and diagnostics.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=889